Copyright © 2010 Karen G. Heal and Andrew W. Taylor-Robinson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. N. Sheikh, M. Al-Shamisi, and W. J. W. Morrow, “Delivery systems for molecular vaccination,” Current Opinion in Molecular Therapeutics, vol. 2, no. 1, pp. 37–54, 2000. View at Scopus
2. C. S. Schmidt, W. J. W. Morrow, and N. A. Sheikh, “Smart adjuvants: mechanisms of action,” Expert Review of Vaccines, vol. 6, no. 3, pp. 391–400, 2007.
3. S. Raychaudhuri and W. J. W. Morrow, “Can soluble antigens induce $\text{CD}{8}^{+}$ cytotoxic T-cell responses? A paradox revisited,” Immunology Today, vol. 14, no. 7, pp. 344–348, 1993. View at Scopus
4. E. A. Keukens, T. de Vrije, C. van den Boom, et al., “Molecular basis of glycoalkaloid induced membrane disruption,” Biochimica et Biophysica Acta, vol. 1240, no. 2, pp. 216–228, 1995. View at Publisher · View at Google Scholar · View at Scopus
5. E. A. Keukens, T. de Vrije, L. A. Jansen, et al., “Glycoalkaloids selectively permeabilize cholesterol containing membranes,” Biochimica et Biophysica Acta, vol. 1279, no. 2, pp. 243–250, 1996. View at Publisher · View at Google Scholar · View at Scopus
6. N. S. Hyslop and A. W. Morrow, “The influence of aluminium hydroxide content, dose volume and the inclusion of saponin on the efficacy of inactivated foot-and-mouth disease vaccines,” Research in Veterinary Science, vol. 10, no. 2, pp. 109–120, 1969. View at Scopus
7. C. M. Rick, J. W. Uhlig, and A. D. Jones, “High alpha-tomatine content in ripe fruit of Andean Lycopersicon esculentum var. cerasiforme: developmental and genetic aspects,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 12877–12881, 1994.
8. P. Rajananthanan, G. S. Attard, N. A. Sheikh, and W. J. W. Morrow, “Evaluation of novel aggregate structures as adjuvants: composition, toxicity studies and humoral responses,” Vaccine, vol. 17, no. 7-8, pp. 715–730, 1999. View at Publisher · View at Google Scholar · View at Scopus
9. J. G. Breman, “Eradicating malaria,” Science Progress, vol. 92, no. 1, pp. 1–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
10. A. W. Taylor-Robinson, “Exoerythrocytic malaria vaccine development: understanding host-parasite immunobiology underscores strategic success,” Expert Review of Vaccines, vol. 1, no. 3, pp. 317–340, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. A. W. Taylor-Robinson and E. C. Smith, “A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection,” Immunological Reviews, vol. 171, pp. 105–123, 1999. View at Publisher · View at Google Scholar · View at Scopus
12. A. W. Taylor-Robinson, “Immunity to liver stage malaria: considerations for vaccine design,” Immunologic Research, vol. 27, no. 1, pp. 53–69, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. P. Romero, J. L. Maryanski, G. Corradin, R. S. Nussenzweig, V. Nussenzweig, and F. Zavala, “Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria,” Nature, vol. 341, no. 6240, pp. 323–326, 1989. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. W. R. Weiss, J. A. Berzofsky, R. A. Houghten, M. Sedegah, M. Hollindale, and S. L. Hoffman, “A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei,” Journal of Immunology, vol. 149, no. 6, pp. 2103–2109, 1992. View at Scopus
15. J. A. Stoute, M. Slaoui, D. G. Heppner, et al., “A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria,” New England Journal of Medicine, vol. 336, no. 2, pp. 86–91, 1997. View at Publisher · View at Google Scholar · View at Scopus
16. P. Sun, R. Schwenk, K. White, et al., “Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific $\text{CD}{4}^{+}$ and $\text{CD}{8}^{+}$ T cells producing IFN-$\gamma$,” Journal of Immunology, vol. 171, no. 12, pp. 6961–6967, 2003. View at Scopus
17. P. Rajananthanan, G. S. Attard, N. A. Sheikh, and W. J. W. Morrow, “Novel aggregate structure adjuvants modulate lymphocyte proliferation and Th1 and Th2 cytokine profiles in ovalbumin immunized mice,” Vaccine, vol. 18, no. 1-2, pp. 140–152, 1999. View at Publisher · View at Google Scholar · View at Scopus
18. A. W. Taylor-Robinson and R. S. Phillips, “Functional characterization of protective $\text{CD}{4}^{+}$ T-cell clones reactive to the murine malaria parasite Plasmodium chabaudi,” Immunology, vol. 77, no. 1, pp. 99–105, 1992. View at Scopus
19. K. G. Heal, H. R. Hill, P. G. Stockley, M. R. Hollingdale, and A. W. Taylor-Robinson, “Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids,” Vaccine, vol. 18, no. 3-4, pp. 251–258, 1999. View at Publisher · View at Google Scholar · View at Scopus
20. K. G. Heal, N. A. Sheikh, M. R. Hollingdale, W. J. W. Morrow, and A. W. Taylor-Robinson, “Potentiation by a novel alkaloid glycoside adjuvant of a protective cytotoxic T cell immune response specific for a preerythrocytic malaria vaccine candidate antigen,” Vaccine, vol. 19, no. 30, pp. 4153–4161, 2001. View at Publisher · View at Google Scholar · View at Scopus
21. W. L. Brown, R. A. Mastico, M. Wu, et al., “RNA bacteriophage capsid-mediated drug delivery and epitope presentation,” Intervirology, vol. 45, no. 4–6, pp. 371–380, 2002. View at Publisher · View at Google Scholar · View at Scopus
22. A. W. Taylor-Robinson and R. S. Phillips, “Th1 and Th2 $\text{CD}{4}^{+}$ T cell clones specific for Plasmodium chabaudi but not for an unrelated antigen protect against blood stage P. chabaudi infection,” European Journal of Immunology, vol. 24, no. 1, pp. 158–164, 1994.
23. L. Schofield, J. Villaquiran, A. Ferreira, H. Schellekens, R. Nussenzweig, and V. Nussenzweig, “$\gamma$-interferon, $\text{CD}{8}^{+}$ T cells and antibodies required for immunity to malaria sporozoites,” Nature, vol. 330, no. 6149, pp. 664–666, 1987. View at Scopus
24. W. R. Weiss, M. Sedegah, R. L. Beaudoin, L. H. Miller, and M. F. Good, “$\text{CD}{8}^{+}$ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 2, pp. 573–576, 1988. View at Scopus
25. S. L. Hoffman, D. Isenbarger, G. W. Long, et al., “Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes,” Science, vol. 244, no. 4908, pp. 1078–1081, 1989. View at Scopus
26. O. Jobe, J. Lumsden, A.-K. Mueller, et al., “Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex class I-dependent interferon-$\gamma$-producing $\text{CD}{8}^{+}$ T cells,” Journal of Infectious Diseases, vol. 196, no. 4, pp. 599–607, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
27. A. Ferreira, L. Schofield, V. Enea, et al., “Inhibition of development of exoerythrocytic froms of malaria parasites by $\gamma$-interferon,” Science, vol. 232, no. 4752, pp. 881–884, 1986. View at Scopus
28. S. Mellouk, R. K. Maheshwari, A. Rhodes-Feuillette, et al., “Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures,” Journal of Immunology, vol. 139, no. 12, pp. 4192–4195, 1987. View at Scopus
29. M. C. Seguin, F. W. Klotz, I. Schneider, et al., “Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon $\gamma$ and $\text{CD}{8}^{+}$ T cells,” Journal of Experimental Medicine, vol. 180, no. 1, pp. 353–358, 1994. View at Publisher · View at Google Scholar · View at Scopus
30. M. Sedegah, F. Finkelman, and S. L. Hoffman, “Interleukin 12 induction of interferon $\gamma$-dependent protection against malaria,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 22, pp. 10700–10702, 1994. View at Publisher · View at Google Scholar · View at Scopus
31. R. K. Maheshwari, C. W. Czarniecki, G. P. Dutta, S. K. Puri, B. N. Dhawan, and M. Friedman, “Recombinant human gamma interferon inhibits simian malaria,” Infection and Immunity, vol. 53, no. 3, pp. 628–630, 1986. View at Scopus
32. S. L. Hoffman, J. M. Crutcher, S. K. Puri, et al., “Sterile protection of monkeys against malaria after administration of interleukin-12,” Nature Medicine, vol. 3, no. 1, pp. 80–83, 1997. View at Publisher · View at Google Scholar · View at Scopus
33. S. Mellouk, S. J. Green, C. A. Nacy, and S. L. Hoffman, “IFN-$\gamma$ inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism,” Journal of Immunology, vol. 146, no. 11, pp. 3971–3976, 1991. View at Scopus
34. S. Mellouk, S. L. Hoffman, Z. Z. Liu, P. de la Vega, T. R. Billiar, and A. K. Nussler, “Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin,” Infection and Immunity, vol. 62, no. 9, pp. 4043–4046, 1994. View at Scopus
35. J. Renggli, M. Hahne, H. Matile, B. Betschart, J. Tschopp, and G. Corradin, “Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity,” Parasite Immunology, vol. 19, no. 3, pp. 145–148, 1997. View at Scopus
36. D. L. Doolan and N. Martinez-Alier, “Immune response to pre-erythrocytic stages of malaria parasites,” Current Molecular Medicine, vol. 6, no. 2, pp. 169–185, 2006. View at Publisher · View at Google Scholar · View at Scopus
37. U. Krzych and J. Schwenk, “The dissection of CD8 T cells during liver-stage infection,” Current Topics in Microbiology and Immunology, vol. 297, no. 1, pp. 1–24, 2005. View at Scopus
38. A. W. Taylor-Robinson and W. J. W. Morrow, “Tomatine as an adjuvant in malaria vaccine development,” Drugs of the Future, vol. 27, no. 4, pp. 391–402, 2002.
39. W. J. W. Morrow, Y.-W. Yang, and N. A. Sheikh, “Immunobiology of the Tomatine adjuvant,” Vaccine, vol. 22, no. 19, pp. 2380–2384, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
40. D. L. Doolan and S. L. Hoffman, “The complexity of protective immunity against liver-stage malaria,” Journal of Immunology, vol. 165, no. 3, pp. 1453–1462, 2000. View at Scopus